Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Development of second-generation VEGFR tyrosine kinase inhibitors: current status.

Development of second-generation VEGFR tyrosine kinase inhibitors: current status. Curr Oncol Rep. 2011 Apr; 13(2):103-11.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.